| 3.18 0 (0%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.72 | 1-year : | 4.35 |
| Resists | First : | 3.19 | Second : | 3.72 |
| Pivot price | 3.16  |
|||
| Supports | First : | 3.15 | Second : | 3.13 |
| MAs | MA(5) : | 3.18 |
MA(20) : | 3.16 |
| MA(100) : | 2.85 |
MA(250) : | 2.84 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 88.8 |
D(3) : | 91.6 |
| RSI | RSI(14): 64.7 | |||
| 52-week | High : | 4.17 | Low : | 1.1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ESPR ] has closed below upper band by 21.8%. Bollinger Bands are 91.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 34 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.18 - 3.2 | 3.2 - 3.21 |
| Low: | 3.14 - 3.16 | 3.16 - 3.18 |
| Close: | 3.15 - 3.18 | 3.18 - 3.21 |
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.
Fri, 31 Jul 2026
Vanguard Capital Management (ESPR) reports 13.1M-share, 5.08% stake in Esperion - Stock Titan
Mon, 27 Jul 2026
Esperion Therapeutics Inc (ESPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sun, 26 Jul 2026
Esperion Therapeutics Inc (ESPR) Cash Flow - TradingKey
Thu, 23 Jul 2026
Esperion Therapeutics, Inc. SEC Filing (Jul 23, 2026) - Stock Titan
Thu, 16 Jul 2026
Esperion Therapeutics, Inc. SEC Filing (Jul 16, 2026) - Stock Titan
Tue, 14 Jul 2026
News On Esperion Therapeutics Inc. (ESPR) Now Under ESPR.XX - moomoo.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 258 (M) |
| Shares Float | 235 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 71.5 (%) |
| Shares Short | 17,400 (K) |
| Shares Short P.Month | 18,710 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.21 |
| Profit Margin | -1.8 % |
| Operating Margin | -8.3 % |
| Return on Assets (ttm) | 12 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 23.2 % |
| Gross Profit (p.s.) | 0.93 |
| Sales Per Share | 1.62 |
| EBITDA (p.s.) | 0.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -50 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -2.65 |
| Price to Sales | 1.95 |
| Price to Cash Flow | -45.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|